Obiettivo Approximately 50 million people worldwide have epilepsy, an illness characterized by recurrent seizures. The estimated proportion of the general population with active epilepsy is between 4 and 10 per 1000 people. Globally, an estimated 2.4 million people are diagnosed with epilepsy each year.When patients suffer generalized convulsions there is a risk for them of being injured or having a cardiac arrest. Caregivers (usually patients’ relatives) reduce this risk by being alert and applying techniques such as holding the patients, putting them in a certain stance or providing them with the prescribed drugs. The problem worsens when seizures occur at night-time.Caregivers usually sleep in the same bedroom as patients and cannot rest due to the constant concern, leading to inconveniences such as loss of privacy, bad resting and higher risk for patients. This project aims to improve the lives of people affected by epilepsy, both patients and caregivers, providing them with an effective and unobtrusive device to monitor patients and alert caregivers during night-time seizures.This project consists on a patient-self-daptive system to detect, video-record and alert caregivers of night-time seizures, linked to a private cloud platform for medical tracking of patients and big data exploitation. The main innovative characteristics of SEIZSAFE are:• Patient-self-adaptive and self-learning algorithm for seizure detection• Camera and cloud platform for doctors• Reduced-cost technology• Medical validationThe present project aims to expand SEIZSAFE in the European market. Considering a global market size of 1.2M epilepsy patients suffering night-time seizures, ENCORE foresees the uptake of 6.5% of the market in 5 years, which means 80,000 users by the end of 2022. Campo scientifico humanitieslanguages and literaturegeneral language studiesmedical and health scienceshealth scienceshealth care serviceseHealthmedical and health sciencesbasic medicineneurologyepilepsymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencescomputer and information sciencesdata sciencebig data Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Argomento(i) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-2-2016-2017 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore ENCORE LAB SL Contribution nette de l'UE € 599 462,50 Indirizzo AVDA ZARAGOZA 18, 1º OF. 2 Logrono Spagna Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Noreste La Rioja La Rioja Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 856 375,00
